The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling

Abstract Acute myeloid leukemia (AML) is a highly aggressive hematologic cancer with poor survival across a broad range of molecular subtypes. Development of efficacious and well-tolerable therapies encompassing the range of mutations that can arise in AML remains an unmet need. The bromo- and extra...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alexander R. Marr, Madeline Halpin, Dominique L. Corbin, Yerdanos Asemelash, Steven Sher, Britten K. Gordon, Ethan C. Whipp, Shaneice Mitchell, Bonnie K. Harrington, Shelley Orwick, Samon Benrashid, Virginia M. Goettl, Vedat Yildiz, Andrew D. Mitchell, Olivia Cahn, Alice S. Mims, Karilyn T. M. Larkin, Meixao Long, James Blachly, Jennifer A. Woyach, Rosa Lapalombella, Nicole R. Grieselhuber
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-03-01
Col·lecció:	Experimental Hematology & Oncology
Matèries:	AML Dinaciclib PLX51107 Wnt signaling β-catenin Resistance
Accés en línia:	https://doi.org/10.1186/s40164-024-00483-w
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!